AtriCure Announces First Patient Enrollment in the DEEP IDE Trial Restart
The trial is intended to establish the safety and effectiveness of a dual epicardial and endocardial ablation procedure for patients with persistent or long-standing persistent atrial fibrillation
The DEEP trial is a prospective, multicenter, single arm, investigational device exempt (IDE) study to evaluate the safety and efficacy of the DEEP procedure in treating persistent and long-standing persistent atrial fibrillation. The DEEP procedure utilizes the specialized skills of both the cardiac surgeon and electrophysiologist (EP) for more severe cases of Afib, which have historically been the most difficult patients to treat. Up to 220 patients will be enrolled at up to 30 hospitals. Currently, 48 patients have been treated in the trial.
The global principal investigators for this trial are Dr.
“The DEEP trial brings electrophysiologists and cardiac surgeons
together as a team in an effort to establish a safe and effective care
pathway for patients presenting with persistent or long-standing
persistent Afib. We are excited about the restart of enrollment in this
important trial,” said Professor
“The DEEP trial reinforces AtriCure’s commitment to continue to expand
the presence in minimally invasive treatment of persistent and
long-standing persistent patients and to improve the lives of these
difficult to treat patients,” said
Senior Director, Corporate Marketing and Communications
Senior Vice President and Chief Financial Officer